Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10126548 | PMC |
| http://dx.doi.org/10.1007/s00296-023-05332-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Inhibition of insulin degrading enzyme suppresses osteoclast hyperactivity via enhancing Nrf2-dependent antioxidant response in glucocorticoid-induced osteonecrosis of the femoral head.
Mol Med
July 2024
Department of Joint Surgery, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, 250012, Shandong, China.
Background: Osteoclast hyperactivation due to the pathological overproduction of reactive oxygen species (ROS) stimulated by glucocorticoids (GCs) is one of the key drivers behind glucocorticoid-induced osteonecrosis of the femoral head (GIONFH). The insulin degrading enzyme (IDE), a conserved Zn metallo-endopeptidase, facilitates the DNA binding of glucocorticoid receptor and plays a substantial role in steroid hormone-related signaling pathways. However, the potential role of IDE in the pathogenesis of GIONFH is yet undefined.
View Article and Find Full Text PDFOsteonecrosis amid the COVID-19 pandemic.
Rheumatol Int
July 2023
South Kazakhstan Medical Academy, Shymkent, Kazakhstan.
Gambogic amide selectively upregulates TrkA expression and triggers its activation.
Pharmacol Rep
April 2015
Center for Osteonecrosis and Joint Preserving and Reconstruction, Department of Orthopedics, China-Japan Friendship Hospital, Beijing, China. Electronic address:
Background: Gambogic amide is the first identified small molecular agonist for TrkA receptor. It mimics NGF functions by selectively activating TrkA receptor and preventing neuron death. However, its function different from that of NGF remains unknown.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!